Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this large multicenter study, severe hair loss related to psychotropic drug treatment was very rare but occurred more frequently in female patients, with valproic acid showing the highest risk.

In this study, the researchers reviewed psychiatric drugs approved between 2002 and 2022 to analyze trends in drug repurposing, finding an increased application of repurposing methods, especially through fixed-dose combinations, and highlighting technologies like SmartCube® to predict efficacy from animal models.

This study found that opiate use was particularly associated with personality and behavioral disorders, while cannabis and legal highs were linked to psychotic disorders, and legal highs with schizophrenia.

This review discusses various drugs that can cause drug-induced acne, noting specific clinical and histopathologic features, but reports no new clinical findings.

This study found that psychiatric adverse drug reactions were more frequently reported with finasteride than with dutasteride, but it remains unclear if there is a causal relationship.

This article discusses various hair diseases and emphasizes their significant impact despite affecting a small area, but does not report new clinical findings.

This article reviews the condition plica neuropathica, including its manifestations, potential causes, and treatment, but it does not provide new clinical findings.

This study reviews literature indicating that certain drugs used to treat dermatological conditions, such as retinoids and glucocorticoids, may rarely cause psychiatric symptoms like depression and anxiety, which are more commonly observed in patients with skin disorders compared to the general population.

This article presents five cases of valproate-induced hyperammonemic encephalopathy in psychiatric patients treated at the authors' clinic and discusses existing literature on this side effect.

This article argues that psychoactive drugs are often beneficial in treating dermatological conditions with psychiatric or psycho-emotional components but does not present new clinical evidence.

The MHRA announced on 11 May 2026 that it will update the product information for finasteride and dutasteride to include more details on potential psychiatric and sexual side effects, following a review of existing evidence.

In this case series, four adults developed severe, disabling multisymptom illness potentially linked to fluoroquinolone use, which persisted and progressed even after discontinuation of the drug.

Some drugs can cause serious side effects, like hypoglycemia from mix-ups, skin reactions, or depression, and while penicillamine may help rheumatoid arthritis more than auranofin, it has more severe side effects.

In this case report, a 54-year-old male experienced hair loss and discoloration after starting mirtazapine, with full hair regrowth and color restoration occurring within 10 weeks of stopping the medication.

Finasteride and dutasteride may increase the risk of depression and suicidality, so patients should be monitored closely.

This chapter reviews various dermatological drugs and treatments, highlighting adverse effects, with no new clinical findings reported.

This article discusses various forms of hair loss and their psychological impacts, noting the lack of definitive treatments, but reports no new clinical findings.

This case study reports the first extensively interpreted instance of dystrophic telogen effluvium potentially linked to pegylated interferon and ribavirin therapy for chronic hepatitis C, characterized through clinical and trichogram analysis.

This review examines alopecia as a side effect of psychotropic medications, noting that it is typically reversible after stopping the drug, but it reports no new results.

This article discusses homoeopathic management of a case of alopecia areata and reports no new clinical results.

This study found that 5-alpha reductase inhibitors had the highest association with erectile dysfunction reports among medications analyzed in the FDA's national pharmacovigilance database.

This pharmacovigilance study analyzed FAERS data and found that finasteride is more frequently associated with neuropsychiatric reactions like depression and suicide risk, especially in younger men using it for alopecia, compared to dutasteride.

The researchers reported that oral finasteride 1 mg was associated with more frequent reports of sexual adverse events than dutasteride 0.5 mg, particularly after 2012, which may be influenced by the nocebo effect.

Some men experience persistent sexual, neurological, and psychological symptoms after stopping finasteride, but evidence of permanent damage is inconclusive.

This review discusses recent data on the use of anabolic-androgenic steroids and other steroid compounds and reports no new clinical results.

The conclusion is that "trichoknesis" should be recognized as a separate condition from trichodynia, characterized by itching instead of pain.

This article reviews the interconnectedness of the skin and nervous system and discusses various treatment options for psychophysiological skin disorders, reporting no new clinical results.

This review discusses potential mechanisms and treatments for trichodynia, noting a lack of strong literature support and reporting no new clinical results; the authors highlight several hypotheses and available treatment options.

This case report observed that an adolescent female experienced hair loss with fluoxetine and sertraline, which resolved with venlafaxine, suggesting potential alopecia as an adverse reaction to these SSRIs.

This review discusses the off-label use of drugs and emphasizes the need for standardized guidelines due to varying international regulations and safety concerns, but reports no new clinical results.